Gainers
IMARA Inc. (NASDAQ: IMRA) jumped 74.8% to settle at $2.01 on Wednesday after the company announced it entered into an asset purchase agreement with Cardurion Pharmaceuticals to sell tovinontrine and other assets of its PDE9 program for $34.75 million upfront.
Azure Power Global Limited (NYSE: AZRE) shares jumped 35.4% to close at $4.86. Azure Power Global recently announced the resignation of Harsh Shah as CEO.
SelectQuote, Inc. (NYSE: SLQT) rose 28.8% to close at $1.43.
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) gained 27.7% to close at $36.40 amid post-IPO volatility.
Spero Therapeutics, Inc. (NASDAQ: SPRO) shares jumped 26.6% to close at $1.43. Spero Therapeutics shares jumped over 55% on Tuesday after the company received minutes from a Type A meeting with the FDA discussing steps required to resubmit the marketing application for tebipenem HBr.
a.k.a. Brands Holding Corp. (NYSE: AKA) gained 23.7% to settle at $2.92 amid overall market strength as stocks rebound from recent weakness.
Pingtan Marine Enterprise Ltd. (NASDAQ: PME) climbed 23.3% to close at $0.8998.
Nutex Health, Inc. (NASDAQ: NUTX) gained 21.9% to close at $3.17.
Molecular Templates, Inc. (NASDAQ: MTEM) rose 21.8% to close at $0.83. Molecular Templates said on August 31, it received notice from Nasdaq that the company no longer meets minimum bid price requirement.
Reata Pharmaceuticals, Inc. (NASDAQ: RETA) jumped 21.1% to settle at $27.07.
Amyris, Inc. (NASDAQ: AMRS) gained 19.6% to settle at $3.24.
Latch, Inc. (NASDAQ: LTCH) jumped 19.2% to close at $1.24.
Tupperware Brands Corporation (NYSE: TUP) gained 19.2% to settle at $8.77 amid overall market strength as stocks rebound from recent weakness.
Vicarious Surgical Inc. (NASDAQ: RBOT) rose 18.8% to close at $4.37. Vicarious Surgical, last month, posted a Q2 loss of $0.16 per share.
Biophytis S.A. (NASDAQ: BPTS) shares gained 18.1% to close at $1.11 after the company released topline results from its phase 2-3 COVA study evaluating Sarconeos (BIO101) in treating COVID-19-related respiratory failure.
Glaukos Corporation (NYSE: GKOS) climbed 18.5% to close at $57.01 after the company announced topline data for both Phase 3 pivotal trials of iDose TR that successfully achieved its pre-specified primary efficacy endpoints through 3 months in both Phase 3 trials and demonstrated excellent tolerability and a ...
Related tickers: ASO, SIDU, LTCH, VERU, AVCT, ADTH, TMUS, SQFT, CCOI, NUTX, VET, AQST, BPTS, GIII, WLY, COUP, AVTX, MGAM, BIAF, PME, BXRX, SPRO, FAZE, AKA, IMRA, UNAM, SHPH, BSGM, SLQT, GME, SEDG, KSPN, KFY, MCRB, RBOT, SAI, GKOS, CLAQ, TPX, PEN, GPCO, TUP, AZRE, FWBI, AMRS, RETA, GTLB, PATH, HKD, QNRX, GPL, NBEV, VCSA, SPWR, MTEM.
Read Full Article